Main Article Content
Pharmacogenomics, Pharmacogenetics, Pharmacist, Physician, Knowledge, Attitude, UAE, GCC, Arab, MENA
The principal goal of pharmacogenomics (PGx) is to achieve the highest drug efficacy while maintaining a low toxicity profile. Historically, health care systems used to target treatment for all individuals with the same diagnosis using a standardized medication or dose that fits all. However, a recent pattern in medicine has emerged focusing on personalized and precision medicine. For effective implementation of PGx, there is a need for more collaborations between all the stakeholders in the healthcare system to integrate the pharmacogenetics concept into practice. When it comes to the knowledge and attitudes towards pharmacogenomics, the majority of medical professionals, including pharmacists and physicians, appear to lack appropriate knowledge and training. Across the Middle East and Arab Region, only few studies have addressed this topic. The current review objective is to shed light on pharmacists’ and physicians’ knowledge and attitudes towards PGx practice in the UAE, Arab and the Middle East region as compared to the rest of the world. Moreover, highlighting the role of the pharmacists in the application of PGx services and the educational challenges that are faced. Proposed solutions to improve the knowledge gaps will also be discussed. We also aim to provide the international readers as well as the local researchers with a summary of the trends and distribution of the results across these countries.
2. Collins FS, Morgan M, Patrinos A. The Human Genome Project: lessons from large-scale biology. Science. 2003;300(5617):286-290. https://doi.org/10.1126/science.1084564
3. Mota NR, Franke B. 30-year journey from the start of the Human Genome Project to clinical application of genomics in psychiatry: are we there yet? The Lancet Psychiatry. 2020;7(1):7-9. https://doi.org/10.1016/s2215-0366(19)30477-8
4. Wilson BJ, Nicholls SG. The Human Genome Project, and recent advances in personalized genomics. Risk management and healthcare policy. 2015;8:9. https://doi.org/10.2147/rmhp.s58728
5. US National Library of Medicine. What is pharmacogenomics? MedlinePlus Genetics [Internet]. [cited 2021 Sep 19]. Available from: https://medlineplus.gov/genetics/understanding/genomicresearch/pharmacogenomics/
6. Thomas RE. Improving the Care of Older Patients by Decreasing Potentially Inappropriate Medications, Potential Medication Omissions, and Serious Drug Events Using Pharmacogenomic Data about Variability in Metabolizing Many Medications by
Seniors. Geriatrics. 2020;5(4):64. https://doi.org/10.3390/geriatrics5040064
7. Klomp SD, Manson ML, Guchelaar HJ, et al. Phenoconversion of cytochrome P450 metabolism: a systematic review. Journal of Clinical Medicine. 2020;9(9):2890. https://doi.org/10.3390/jcm9092890
8. Snoj J. UAEs population-by nationality. Bq Magazine. 2015;12.
9. Pisanu C, Tsermpini EE, Mavroidi E, et al. Assessment of the pharmacogenomics educational environment in Southeast Europe. Public health genomics. 2014;17(5-6):272-279. https://doi.org/10.1159/000366461
10. Johnson JA, Weitzel KW. Advancing pharmacogenomics as a component of precision medicine: how, where, and who? Clinical Pharmacology & Therapeutics. 2016;99(2):154-156. https://doi.org/10.1002/cpt.273
11. Gurwitz D, Lunshof JE, Dedoussis G, et al. Pharmacogenomics education: International Society of Pharmacogenomics recommendations for medical, pharmaceutical, and health schools deans of education. The Pharmacogenomics Journal.
12. Ginsburg GS, Willard HF. Genomic and personalized medicine: foundations and applications. Translational Research. 2009;154(6):277-287. https://doi.org/10.1016/j.trsl.2009.09.005
13. Klein ME, Parvez MM, Shin JG. Clinical implementation of pharmacogenomics for personalized precision medicine: barriers and solutions. Journal of Pharmaceutical Sciences. 2017;106(9):2368-2379. https://doi.org/10.1016/j.xphs.2017.04.051
14. Roden DM, McLeod HL, Relling MV, et al. Pharmacogenomics. Lancet. 2019;394(10197):521-532. https://doi.org/10.3390/books978-3-0365-2834-2
15. Ehmann F, Caneva L, Prasad K, et al. Pharmacogenomic information in drug labels: European Medicines Agency perspective. The Pharmacogenomics Journal. 2015;15(3):201-210. https://doi.org/10.1038/tpj.2014.86
16. Kim JA, Ceccarelli R, Lu CY. Pharmacogenomic Biomarkers in US FDA-Approved Drug Labels (2000-2020). Journal of Personalized Medicine. 2021;11(3):179. https://doi.org/10.3390/jpm11030179
17. Gage BF, Lesko LJ. Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues. Journal of Thrombosis and Thrombolysis. 2008;25(1):45-51. https://doi.org/10.1007/s11239-007-0104-y
18. Johnson J, Caudle K, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for PharmacogeneticsGuided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. https://doi.org/10.1002/cpt.668
19. McCullough KB, Formea CM, Berg KD, et al. Assessment of the pharmacogenomics educational needs of pharmacists. American Journal of Pharmaceutical Education. 2011;75(3). https://doi.org/10.5688/ajpe75351
20. US Food and Drug Administration. Table of Pharmacogenomic Biomarkers in Drug Labeling. FDA [Internet]. 2021 Aug 18 [cited 2021 Sep 19]; Available from: https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkersdrug-labeling
21. Abul-Husn NS, Obeng AO, Sanderson SC, et al. Implementation and utilization of genetic testing in personalized medicine.Pharmacogenomics and Personalized Medicine. 2014;7:227. https://doi.org/10.2147/pgpm.s48887
22. Dickmann LJ, Ware JA. Pharmacogenomics in the age of personalized medicine. Drug Discovery Today: Technologies. 2016;21:11-6.
23. Relling MV, Klein TE, Gammal RS, et al. The Clinical Pharmacogenetics Implementation Consortium: 10 Years Later. Clinical Pharmacology & Therapeutics. 2020;107(1):171-5. https://doi.org/10.1002/cpt.1651
24. National Institute of General Medical Sciences. National Institute of General Medical Sciences (NIGMS). [cited 2022 Oct 24]. Available from: https://nigms.nih.gov/
25. PharmGKB. PharmGKB. [cited 2022 Oct 24]. Available from: https://www.pharmgkb.org/
26. Clinical Pharmacogenetics Implementation Consortium. [cited 2022 Oct 24]. Available from: https://cpicpgx.org/
27. NIH funds clinical trials using genomics to treat chronic diseases. National Institutes of Health (NIH). 2019 [cited 2022 Oct 24]. Available from: https://www.nih.gov/news-events/news-releases/nih-funds-clinical-trials-using-genomics-treat-chronicdiseases
28. Abou Diwan E, Zeitoun RI, Abou Haidar L, et al. Implementation and obstacles of pharmacogenetics in clinical practice: an international survey. British Journal of Clinical Pharmacology. 2019;85(9):2076-88. https://doi.org/10.1111/bcp.13999
29. Peterson JF, Field JR, Shi Y, et al. Attitudes of clinicians following large-scale pharmacogenomics implementation. The pharmacogenomics Journal. 2016;16(4):393-8. https://doi.org/10.1038/tpj.2015.57
30. Campion M, Goldgar C, Hopkin RJ, et al. Genomic education for the next generation of health-care providers. Genet Med. 2019;21(11):2422-2430. https://doi.org/10.1038/s41436-019-0548-4
31. Albitar L, Alchamat GA. Pharmacogenetics: Knowledge assessment amongst Syrian pharmacists and physicians. BMC Health Services Research. 2021;21(1):1-8. https://doi.org/10.1186/s12913-021-07040-9
32. Lee KC, Hudmon KS, Ma JD, et al. Evaluation of a shared pharmacogenomics curriculum for pharmacy students. Pharmacogenomics. 2015;16(4):315-322. https://doi.org/10.2217/pgs.14.181
33. Yau A, Husain R, Haque M. A systematic review of knowledge, attitude and practice towards pharmacogenomics among doctors. Int J Pharm Res. 2015;7:9-16. https://doi.org/10.5530/jyp.2015.3.3
34. Taber KAJ, Dickinson BD. Pharmacogenomic knowledge gaps and educational resource needs among physicians in selected specialties. Pharmacogenomics and Personalized Medicine. 2014;7:145. https://doi.org/10.2147/pgpm.s63715
35. Muflih S, Alshogran OY, Al-Azzam S, et al. Physicians’ Knowledge and Attitudes Regarding Point-of-Care Pharmacogenetic Testing: A Hospital-Based Cross-Sectional Study. Pharmacogenomics and Personalized Medicine. 2021;14:655. https://doi.
36. Klitzman R, Chung W, Marder K, et al. Attitudes and practices among internists concerning genetic testing. Journal of Genetic Counseling. 2013;22(1):90-100. https://doi.org/10.1007/s10897-012-9504-z
37. Rahma AT, Elsheik M, Ali BR, et al. Knowledge, attitudes, and perceived barriers toward genetic testing and pharmacogenomics among healthcare workers in the United Arab Emirates: a Cross-Sectional Study. Journal of Personalized Medicine.
38. Elewa H, Alkhiyami D, Alsahan D, et al. A survey on the awareness and attitude of pharmacists and doctors towards the application of pharmacogenomics and its challenges in Q atar. Journal of Evaluation in Clinical Practice. 2015;21(4):703-709.
39. Albassam A, Alshammari S, Ouda G, et al. Knowledge, perceptions and confidence of physicians and pharmacists towards pharmacogenetics practice in Kuwait. PLoS One. 2018;13(9):e0203033. https://doi.org/10.1371/journal.pone.0203033
40. Shuldiner AR, Palmer K, Pakyz RE, et al. Implementation of pharmacogenetics: The University of Maryland personalized antiplatelet pharmacogenetics program. In: American Journal of Medical Genetics Part C: Seminars in Medical Genetics. Wiley
Online Library; 2014;76-84. https://doi.org/10.1002/ajmg.c.31396
41. Alsafar H, Islayem D, Almansoori R, et al. Perceptions on Genetic and Genome Screening among College Students in the Emirates of Abu Dhabi. DMJ. 2021;4(3):263-272. https://doi.org/10.1159/000518623
42. Garrison Jr LP, Carlson RJ, Carlson JJ, et al. A review of public policy issues in promoting the development and commercialization of pharmacogenomic applications: challenges and implications. Drug Metabolism Reviews. 2008;40(2):377-401. https://doi.
43. Streetman DS. Emergence and evolution of pharmacogenetics and pharmacogenomics in clinical pharmacy over the past 40 years. Annals of Pharmacotherapy. 2007;41(12):2038-2041. https://doi.org/10.1345/aph.1k273
44. Christaki E, Giamarellos-Bourboulis EJ. The beginning of personalized medicine in sepsis: small steps to a bright future. ClinicalGenetics. 2014;86(1):56-61. https://doi.org/10.1111/cge.12368
45. Rahma AT, Elsheik M, Elbarazi I, et al. Knowledge and attitudes of medical and health science students in the United Arab Emirates toward genomic medicine and pharmacogenomics: A cross-sectional study. Journal of Personalized Medicine.
46. Zawiah M, Yousef AM, Al-Ashwal FY, et al. Pharmacogenetics: a perspective and preparedness of Pharm-D and medical students in Jordan. Pharmacogenetics and Genomics. 2021;31(6):125-132. https://doi.org/10.1097/fpc.0000000000000430
47. Moen M, Lamba J. Assessment of healthcare students’ views on pharmacogenomics at the University of Minnesota. Pharmacogenomics. 2012;13(13):1537-1545. https://doi.org/10.2217/pgs.12.139
48. Nagy M, Lynch M, Kamal S, et al. Assessment of healthcare professionals’ knowledge, attitudes, and perceived challenges of clinical pharmacogenetic testing in Egypt. Personalized Medicine. 2020;17(4):251-260. https://doi.org/10.2217/pme-2019-
49. Mai Y, Mitropoulou C, Papadopoulou XE, et al. Critical appraisal of the views of healthcare professionals with respect to pharmacogenomics and personalized medicine in Greece. Personalized Medicine. 2014;11(1):15-26. https://doi.org/10.2217/
50. Jarrar Y, Lee SJ. Demand for Pharmacogenomics and Personalized Medicine in the United Arab Emirates. Journal of Personalized Medicine. Multidisciplinary Digital Publishing Institute; 2022;12(1):104. https://doi.org/10.3390/jpm12010104
51. Rahma AT, Elbarazi I, Ali BR, et al. Genomics and pharmacogenomics knowledge, attitude and practice of pharmacists working in United Arab Emirates: findings from focus group discussions—a qualitative study. Journal of Personalized Medicine.
52. Emirati Genome Program. [cited 2021 Dec 13]. Available from: https://emiratigenomeprogram.ae/
53. Ali Z, Elewa H. The Effect of CYP2C19 and Nongenetic Factors on Clopidogrel Responsiveness in the MENA Region: A Systematic Review. Clin Appl Thromb Hemost. 2019;25:1076029619875520. https://doi.org/10.1177/1076029619875520
54. AlEjielat R, Ejielat Z, Andrawes S, et al. An evaluation of the knowledge, opinions, expectations and concerns toward pharmacogenomics among Jordanian pharmacists. Personalized medicine. 2016;13(2):143-154. https://doi.org/10.2217/
55. N Al-Eitan L, A Haddad Y. Emergence of pharmacogenomics in academic medicine and public health in Jordan: History, present state and prospects. Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics).
56. Jarrar Y, Mosleh R, Hawash M, et al. Knowledge and Attitudes of Pharmacy Students Towards Pharmacogenomics Among Universities in Jordan And West Bank of Palestine. Pharmgenomics Pers Med. 2019;12(1):247-255. https://doi.org/10.2147/
57. Jarrar Y, Musleh R, Ghanim M, et al. Assessment of the need for pharmacogenomics education among pharmacists in the West Bank of Palestine. Int J Clin Pract. 2021;75(9):e14435. https://doi.org/10.1111/ijcp.14435
58. Roederer MW, Van Riper M, Valgus J, et al. Knowledge, attitudes and education of pharmacists regarding pharmacogenetic testing. Personalized Medicine. 2012;9(1):19-27. https://doi.org/10.2217/pme.11.87
59. Radouani F, Zass L, Hamdi Y, et al. A review of clinical pharmacogenetics Studies in African populations. Per Med. 2020;17(2):155-170.
60. Dandara C, Masimirembwa C, Haffani YZ, et al. African Pharmacogenomics Consortium: Consolidating pharmacogenomics knowledge, capacity development and translation in Africa. AAS Open Res. 2019;2(1):19. https://doi.org/10.12688/
61. Zgheib NK, Arawi T, Mahfouz RA, et al. Attitudes of health care professionals toward pharmacogenetic testing. Mol Diagn Ther. 2011;15(2):115-122. https://doi.org/10.1007/bf03256401
62. Thomas SM. Society and ethics - the genetics of disease. Curr Opin Genet Dev. 2004;14(3):287-291. https://doi.org/10.1016/j.gde.2004.04.014
63. Tadmouri GO, Ali MTA, Ali SAH, et al. CTGA: the database for genetic disorders in Arab populations. Nucleic acids research. 2006;34(suppl_1):D602-606. https://doi.org/10.1093/nar/gkj015
64. Team SGP. The Saudi Human Genome Program: An oasis in the desert of Arab medicine is providing clues to genetic disease. IEEE Pulse. 2015;6(6):22-26. https://doi.org/10.1109/mpul.2015.2476541
65. Abu-Elmagd M, Assidi M, Schulten HJ, et al. Individualized medicine enabled by genomics in Saudi Arabia. BMC Medical Genomics. 2015;8(1):S3. https://doi.org/10.1186/1755-8794-8-s1-s3
66. Algahtani M. Knowledge, perception, and application of pharmacogenomics among hospital pharmacists in Saudi Arabia. Risk Management and Healthcare Policy. 2020;13(1):1279. https://doi.org/10.2147/rmhp.s267492
67. Bagher AM, Neamatallah T, Balto G, et al. Knowledge, perception, and confidence of hospital pharmacists toward pharmacogenetics in Jeddah, Kingdom of Saudi Arabia. Saudi Pharm J. 2021;29(1):53-58. https://doi.org/10.1016/j.
68. Arafah A, Rehman MU, Syed W, et al. Knowledge, Attitude and Perception of Pharmacy Students towards Pharmacogenomics and Genetics: An Observational Study from King Saud University. Genes (Basel). 2022;13(2):269. https://doi.org/10.3390/
69. Alhaddad ZA, AlMousa HA, Younis NS. Pharmacists’ Knowledge, and Insights in Implementing Pharmacogenomics in Saudi Arabia. Int J Environ Res Public Health. 2022;19(16). https://doi.org/10.3390/ijerph191610073
70. Salari K, Karczewski KJ, Hudgins L, et al. Evidence that personal genome testing enhances student learning in a course on genomics and personalized medicine. PLoS One. 2013;8(7):e68853. https://doi.org/10.1371/journal.pone.0068853
71. Higgs JE, Andrews J, Gurwitz D, et al. Pharmacogenetics education in British medical schools. Genomic Med. 2008;2(3-4):101-105. https://doi.org/10.1007/s11568-009-9032-6
72. Alsaloumi L, Abdi A, Tosun Ö, et al. Pharmacogenomics-based practice in North Cyprus: its adoption by pharmacists and their attitudes and knowledge. Int J Clin Pharm. 2019;41(5):1299-1306. https://doi.org/10.1007/s11096-019-00868-6
73. Dodson C. Knowledge and attitudes concerning pharmacogenomics among healthcare professionals. Personalized Medicine. 2011;8(4):421-428. https://doi.org/10.2217/pme.11.28
74. Kuo GM, Ma JD, Lee KC, et al. Institutional profile: University of California San Diego pharmacogenomics education program (pharmgenedTM): bridging the gap between science and practice. Pharmacogenomics. 2011;12(2):149-153. https://doi.
75. Bannur Z, Bahaman S, Salleh MZ, et al. Pharmacogenomics based practice in Malaysia: the attitude, knowledge and adoption by the healthcare professionals. IIUM Medical Journal Malaysia. 2014;13(1). https://doi.org/10.31436/imjm.v13i1.491
76. Muzoriana N, Gavi S, Nembaware V, et al. Knowledge, attitude, and perceptions of pharmacists and pharmacy students towards pharmacogenomics in Zimbabwe. Pharmacy. 2017;5(3):36. https://doi.org/10.3390/pharmacy5030036
77. Yau A, Abd Aziz AB, Haque M. Knowledge, Attitude and Practice Concerning Pharmacogenomics among Pharmacists: A Systematic Review. Journal of Young Pharmacists. 2015;7(3). https://doi.org/10.5530/jyp.2015.3.3
78. Newton R, Lithgow J, Li Wan Po A, et al. How will pharmacogenetics impact on pharmacy practice? pharmacists’ views and educational priorities. London: NHS, NGEDC and RPSGB. 2007;
79. Zembles T. An inservice program on pharmacogenetics to individualize drug therapy. American journal of pharmaceutical education. 2010;74(1). https://doi.org/10.5688/aj740110
80. McMahon T, Tucci J. Percepciones de los farmacéuticos en Victoria, Australia sobre la farmacogenética y sus implicaciones. Pharmacy Practice (Internet). 2011;9(3):141-147.
81. Rahawi S, Naik H, Blake KV, et al. Knowledge and attitudes on pharmacogenetics among pediatricians. Journal of Human Genetics. 2020;65(5):437-444. https://doi.org/10.1038/s10038-020-0723-0
82. Perwitasari DA, Novitasari SL, Septiantoro BP, et al. Knowledge awareness and attitude of pharmacists toward pharmacogenetic practice: perspective of community and hospital in Yogyakarta, Indonesia. J Community Med Health Educ. 2017;7(568):2161-
83. Cavallari LH, Lee CR, Beitelshees AL, et al. Multisite investigation of outcomes with implementation of CYP2C19 genotypeguided antiplatelet therapy after percutaneous coronary intervention. JACC: Cardiovascular Interventions. 2018;11(2):181-
84. Feero WG, Kuo GM, Jenkins JF, et al. Pharmacist education in the era of genomic medicine. Journal of the American Pharmacists Association. 2012;52(5):e113-121. https://doi.org/10.1331/japha.2012.12149
85. Russell Teagarden J, Stanek EJ. On pharmacogenomics in pharmacy benefit management. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2012;32(2):103-111. https://doi.org/10.1002/phar.1039
86. Owusu-Obeng A, Weitzel KW, Hatton RC, et al. Emerging roles for pharmacists in clinical implementation of pharmacogenomics. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2014;34(10):1102-1112. https://doi.org/10.1002/
87. Haga SB, Allen LaPointe NM, Moaddeb J. Challenges to integrating pharmacogenetic testing into medication therapy management. Journal of Managed Care & Specialty Pharmacy. 2015;21(4):346-352. https://doi.org/10.18553/jmcp.2015.21.4.346
88. Caudle KE, Gammal RS, Whirl-Carrillo M, et al. Evidence and resources to implement pharmacogenetic knowledge for precision medicine. American Journal of Health-System Pharmacy. 2016;73(23):1977-1985. https://doi.org/10.2146/ajhp150977
89. Crabtree B, Bootman JL, Boyle CJ, et al. Aligning the AACP Strategic Engagement Agenda with Key Federal Priorities in Health: Report of the 2016-17 Argus Commission. AJPE. 2017;81(8). https://doi.org/10.5688/ajpes15
90. Nutter SC, Gálvez‐Peralta M. Pharmacogenomics: From classroom to practice. Mol Genet Genomic Med. 2018;6(3):307-313. https://doi.org/10.1002/mgg3.417
91. Physicians’ Preparedness for Integration of Genomic and Pharmacogenetic Testing into Practice Within a Major Healthcare System | Genetic Testing and Molecular Biomarkers. [cited 2021 Dec 16]. Available from: https://www.liebertpub.com/doi/
92. Sheldon J, Ou W. The real informatics challenges of personalized medicine: not just about the number of central processing units. Personalized Medicine. 2013;10(7):639-645. https://doi.org/10.2217/pme.13.16
93. Hippman C, Nislow C. Pharmacogenomic Testing: Clinical Evidence and Implementation Challenges. J Pers Med. 2019;9(3):40. https://doi.org/10.3390/jpm9030040
94. Physician Barriers to Incorporating Pharmacogenetic Treatment Strategies for Nicotine Dependence Into Clinical Practice - Schnoll - 2011 - Clinical Pharmacology & Therapeutics - Wiley Online Library. [cited 2021 Dec 16]. Available from: https://
95. Haidar CE, Hoffman JM, Gammal RS, et al. Development of a postgraduate year 2 pharmacy residency in clinical pharmacogenetics. American Journal of Health-System Pharmacy. 2017;74(6):409-415. https://doi.org/10.2146/ajhp160174
96. Chang A, Nelson R, Brixner D. Advancing pharmacy practice by reducing gaps in pharmacogenetic education. American Journal of Health-System Pharmacy. 2019;76(5):320-326. https://doi.org/10.1093/ajhp/zxy066
97. Edana Holliday P, Mandy Irvin P. Educational Pharmacogenetics Resources for Pharmacists. 2016 Oct 19 [cited 2021 Dec 16]; Available from: https://www.pharmacytimes.com/view/educational-pharmacogenetics-resources-for-pharmacists
98. Mayhew M, Jablonski M, Li J, et al. Combinatorial pharmacogenomics reduces polypharmacy and medication cost in elderly
patients with anxiety and depression. The American Journal of Geriatric Psychiatry. 2017;25(3):S143-144. https://doi.org/10.1016/j.jagp.2017.01.165